Consequently, the recent development of direct KRAS-G12C inhibitors has gained interest in the utility of combining KRAS inhibition with immunotherapy, especially for PD-1 refractory KRAS-STK11 and KRAS-KEAP1 co-mutated advanced NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.